- Home
- ESRT vs TVTX Comparison
ESRT vs TVTX Comparison
Compare ESRT & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESRT
- TVTX
- Stock Information
- Founded
- ESRT 2011
- TVTX 2008
- Country
- ESRT United States
- TVTX United States
- Employees
- ESRT N/A
- TVTX N/A
- Industry
- ESRT Real Estate Investment Trusts
- TVTX Biotechnology: Pharmaceutical Preparations
- Sector
- ESRT Real Estate
- TVTX Health Care
- Exchange
- ESRT Nasdaq
- TVTX Nasdaq
- Market Cap
- ESRT 1.7B
- TVTX 1.8B
- IPO Year
- ESRT 2013
- TVTX N/A
- Fundamental
- Price
- ESRT $8.66
- TVTX $21.98
- Analyst Decision
- ESRT Hold
- TVTX Strong Buy
- Analyst Count
- ESRT 2
- TVTX 12
- Target Price
- ESRT $11.50
- TVTX $30.08
- AVG Volume (30 Days)
- ESRT 1.3M
- TVTX 1.8M
- Earning Date
- ESRT 02-19-2025
- TVTX 02-20-2025
- Dividend Yield
- ESRT 1.62%
- TVTX N/A
- EPS Growth
- ESRT N/A
- TVTX N/A
- EPS
- ESRT 0.28
- TVTX N/A
- Revenue
- ESRT $763,152,000.00
- TVTX $233,175,000.00
- Revenue This Year
- ESRT N/A
- TVTX $62.88
- Revenue Next Year
- ESRT $1.85
- TVTX $57.60
- P/E Ratio
- ESRT $30.89
- TVTX N/A
- Revenue Growth
- ESRT 3.19
- TVTX 60.55
- 52 Week Low
- ESRT $8.61
- TVTX $5.12
- 52 Week High
- ESRT $11.62
- TVTX $25.29
- Technical
- Relative Strength Index (RSI)
- ESRT 24.25
- TVTX 53.52
- Support Level
- ESRT $9.27
- TVTX $22.48
- Resistance Level
- ESRT $9.30
- TVTX $23.69
- Average True Range (ATR)
- ESRT 0.21
- TVTX 1.22
- MACD
- ESRT -0.05
- TVTX -0.02
- Stochastic Oscillator
- ESRT 4.37
- TVTX 41.10
About ESRT Empire State Realty Trust Inc.
Empire State Realty Trust operates as a pure-play greater New York and Manhattan-focused REIT, featuring its landmark Empire State Building office and observation deck. The company owns and operates around 8.5 million square feet of office space, about 80% of which is located in Manhattan.
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease.